The New Jersey-based company announced Monday that it couldn t find a workaround for technology covered by Verizon s patents, and Vonage s CEO, MichaelSnyder, resigned last week.
In a National Bureau of Economic Research paper, Michael Kremer of Harvard and Christopher Snyder of Dartmouth explain why it is that drug companies, absent a nudge from a subsidy, favor research on drug treatments over research on vaccines.